-
Devastation at Sydney's Bondi beach after deadly shooting
-
AC Milan held by Sassuolo in Serie A
-
Person of interest in custody after deadly shooting at US university
-
Van Dijk wants 'leader' Salah to stay at Liverpool
-
Zelensky in Berlin for high-stakes talks with US envoys, Europeans
-
Norway's Haugan powers to Val d'Isere slalom win
-
Hong Kong's oldest pro-democracy party announces dissolution
-
Gunmen kill 11 at Jewish festival on Australia's Bondi Beach
-
Zelensky says will seek US support to freeze front line at Berlin talks
-
Man who ploughed car into Liverpool football parade to be sentenced
-
Wonder bunker shot gives Schaper first European Tour victory
-
Chile far right eyes comeback as presidential vote opens
-
Gunmen kill 11 during Jewish event at Sydney's Bondi Beach
-
Robinson wins super-G, Vonn 4th as returning Shiffrin fails to finish
-
France's Bardella slams 'hypocrisy' over return of brothels
-
Ka Ying Rising hits sweet 16 as Romantic Warrior makes Hong Kong history
-
Shooting at Australia's Bondi Beach kills nine
-
Meillard leads after first run in Val d'Isere slalom
-
Thailand confirms first civilian killed in week of Cambodia fighting
-
England's Ashes hopes hang by a thread as 'Bazball' backfires
-
Police hunt gunman who killed two at US university
-
Wemby shines on comeback as Spurs stun Thunder, Knicks down Magic
-
McCullum admits England have been 'nowhere near' their best
-
Wembanyama stars as Spurs stun Thunder to reach NBA Cup final
-
Cambodia-Thailand border clashes enter second week
-
Gunman kills two, wounds nine at US university
-
Green says no complacency as Australia aim to seal Ashes in Adelaide
-
Islamabad puts drivers on notice as smog crisis worsens
-
Higa becomes first Japanese golfer to win Asian Tour order of merit
-
Tokyo-bound United plane returns to Washington after engine fails
-
Deja vu? Trump accused of economic denial and physical decline
-
Vietnam's 'Sorrow of War' sells out after viral controversy
-
China's smaller manufacturers look to catch the automation wave
-
For children of deported parents, lonely journeys to a new home
-
Hungary winemakers fear disease may 'wipe out' industry
-
Chile picks new president with far right candidate the front-runner
-
German defence giants battle over military spending ramp-up
-
Knicks reach NBA Cup final as Brunson sinks Magic
-
Quarterback Mendoza wins Heisman as US top college football player
-
Knicks reach NBA Cup final with 132-120 win over Magic
-
Campaigning starts in Central African Republic quadruple election
-
NBA Cavs center Mobley out 2-4 weeks with left calf strain
-
Tokyo-bound United flight returns to Dulles airport after engine fails
-
Hawks guard Young poised to resume practice after knee sprain
-
Salah back in Liverpool fold as Arsenal grab last-gasp win
-
Raphinha extends Barca's Liga lead, Atletico bounce back
-
Glasgow comeback upends Toulouse on Dupont's first start since injury
-
Two own goals save Arsenal blushes against Wolves
-
'Quality' teens Ndjantou, Mbaye star as PSG beat Metz to go top
-
Trump vows revenge after troops in Syria killed in alleged IS ambush
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB